Tuesday July 16, 2019
Home India HC notice to ...

HC notice to DDA on DTC’s plea on Millennium Depot

0
//

New Delhi: The Delhi High Court on Thursday issued notice to DDA on DTC’s plea to approach the land owing agency to “extend the time for change of land use of Millennium Bus Depot by another six months” as the Delhi government has decided not to vacate the site.

A division bench of Chief Justice G. Rohini and Justice Jayant Nath sought response from Delhi Development Corporation (DDA) by September 14 on the plea of Delhi Transport Corporation (DTC).

The DTC sought direction to DDA to change land use of the depot land so that the temporary construction on “O” zone can be made permanent according to the master plan.

2015-08-20_2252_001

The bus depot, built at a cost of Rs.60 crore for the 2010 Commonwealth Games at Yamuna river bed, is to be used for parking buses by changing the land use, the DTC told the court.

In the Aam Aadmi Party’s first stint, Chief Minister Arvind Kejriwal cited environmental concerns to order relocation of DTC’s fleet of buses from the depot but now his government has reversed its stand in its second stint because of “changed scenario”.

The DTC said in spite of best efforts, alternative plots to shift the complete fleet from Millennium Depot have not been made available yet, while more buses are being added to the fleet for which additional parking space is required.

The National Green Tribunal (NGT) has also directed the DTC to augment its fleet for which more space is required from DDA.

2015-08-20_2252

“In view of the changed scenario requiring DTC to augment its fleet by adding more buses, more space is needed. Existing space needs to be protected,” the plea said.

Last year in January, DTC first undertook in high court to relocate the depot to another location, admitting that the entire exercise will cost “Rs.300 crore”. Assuring the court it will abide by the AAP government’s stand, the corporation in an affidavit had sought nine months to finish the relocation.

Later it revised the estimate to 20-26 months even as hectic consultation began with DDA over identifying fresh spots to relocate the depot. The DDA has already handed over plots at Narela, Rohini and Sarai Kale Khan to DTC for this purpose.

In his PIL, environmentalist Anand Arya had opposed the depot being constructed on the floodplains, which had been earmarked in the master plan for recreational use, including a biodiversity park.

(IANS)

Next Story

Delhi High Court Directs Private Clinic to Continue with the Stem Cell Treatment

The clinic, which is administering the medicine, cannot function under the new rules until the licence is duly obtained

0
Order
Delhi High Court. Source- Wikimedia

In an interim relief, the Delhi High Court has directed a private clinic to continue with the stem cell treatment being provided to the patients till its further orders.

The court’s interim direction came while hearing various petitions challenging the Centre’s decision to put stem cell therapy in the category of new drugs.

The petitioners were being provided stem cell treatment in Nutech Mediworld Clinic in Green Park here.

A Division Bench of justices Anu Malhotra and Talwant Singh said that all details of treatment being provided to the petitioners by the clinic be placed on record with an affidavit.

Representational image.

The court has sought the response of Centre and Indian Council of Medical Research to file reply on the petition and listed the matter for September 4 for further hearing.

The court has directed authorities concerned to examine whether the products being administered to the petitioners, prima facie, fall within the scope of the expression ‘new drugs’ as defined under Rule 2(1) (w) of New Drugs and Clinical Trial Rules, 2019 and communicate the view to the petitioners and the said clinic.

Also Read- LG CNS, Microsoft to Develop Cloud-based Enterprise Solutions

On account of the Centre’s fresh notification on ‘New Drugs and Clinical Rule 2019’, some medications used for the treatment would fall under the definition of ‘new drug’ and require approval from the authority concerned.

The clinic, which is administering the medicine, cannot function under the new rules until the licence is duly obtained. (IANS)